At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Tadalafildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tadalafil for the Treatment of Secondary Raynaud's Phenomenon
In Brief
A clinical study evaluating Tadalafil for Raynaud. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRaynaud
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedJan 2009
Primary CompletionFeb 2010
Study CompletionApr 2010
TodayJul 2026
First PostedJan 14, 2009
Enrollment StartSep 1, 2008
Primary CompletionFeb 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.5 years ago
Interventions
Tadalafildrug
Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil